214 related articles for article (PubMed ID: 9885221)
1. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833.
Egashira M; Kawamata N; Sugimoto K; Kaneko T; Oshimi K
Blood; 1999 Jan; 93(2):599-606. PubMed ID: 9885221
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.
Klimecki WT; Taylor CW; Dalton WS
J Clin Immunol; 1995 May; 15(3):152-8. PubMed ID: 7559918
[TBL] [Abstract][Full Text] [Related]
3. No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer.
Hegewisch-Becker S; Staib F; Löning T; Pichlmeier U; Kröger N; Reymann A; Hossfeld DK
Ann Oncol; 1998 Jan; 9(1):85-93. PubMed ID: 9541688
[TBL] [Abstract][Full Text] [Related]
4. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans.
Aggarwal S; Tsuruo T; Gupta S
J Clin Immunol; 1997 Nov; 17(6):448-54. PubMed ID: 9418184
[TBL] [Abstract][Full Text] [Related]
5. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging.
Pilarski LM; Paine D; McElhaney JE; Cass CE; Belch AR
Am J Hematol; 1995 Aug; 49(4):323-35. PubMed ID: 7639278
[TBL] [Abstract][Full Text] [Related]
6. Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias.
Arai Y; Masuda M; Sugawara I; Arai T; Motoji T; Tsuruo T; Oshimi K; Mizoguchi H
Leuk Res; 1997 Apr; 21(4):313-9. PubMed ID: 9150348
[TBL] [Abstract][Full Text] [Related]
7. Lymphoproliferative disorders of natural killer cells.
Oshimi K
Int J Hematol; 1996 Jun; 63(4):279-90. PubMed ID: 8762811
[TBL] [Abstract][Full Text] [Related]
8. P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients.
Lucia MB; Cauda R; Malorni W; Rainaldi G; Tumbarello M; Tacconelli E; Rumi C; Donelli G; Ortona L
Immunol Lett; 1995 Sep; 47(3):223-6. PubMed ID: 8747723
[TBL] [Abstract][Full Text] [Related]
9. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders.
Kobayashi Y; Watanabe N; Oshimi K
Leuk Lymphoma; 1994 Jun; 14(1-2):157-61. PubMed ID: 7920224
[TBL] [Abstract][Full Text] [Related]
10. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Drénou B; Lamy T; Amiot L; Fardel O; Caulet-Maugendre S; Sasportes M; Diebold J; Le Prisé PY; Fauchet R
Blood; 1997 Apr; 89(8):2966-74. PubMed ID: 9108417
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.
Yano S; Sone S; Nishioka Y; Naito M; Tsuruo T; Ogura T
Jpn J Cancer Res; 1994 Feb; 85(2):194-203. PubMed ID: 7511575
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.
Pilarski LM; Yatscoff RW; Murphy GF; Belch AR
Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of peripheral blood natural killer (NK) cells in two patients with CD16+ CD56- NK cell-lineage granular lymphocyte-proliferative disorder].
Egashira M; Kaneko T; Oshimi K; Mizoguchi H; Ishida M
Rinsho Ketsueki; 1995 Feb; 36(2):69-75. PubMed ID: 7536278
[TBL] [Abstract][Full Text] [Related]
14. [Flow cytometric analysis of P-glycoprotein function by rhodamine 123 dye-efflux assay in human leukemia cells].
Kawabata M; Kobayashi H; Mori S; Sekiguchi S; Takemura Y
Rinsho Byori; 1997 Sep; 45(9):891-8. PubMed ID: 9311264
[TBL] [Abstract][Full Text] [Related]
15. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Ludescher C; Hilbe W; Eisterer W; Preuss E; Huber C; Gotwald M; Hofmann J; Thaler J
J Natl Cancer Inst; 1993 Nov; 85(21):1751-8. PubMed ID: 8105101
[TBL] [Abstract][Full Text] [Related]
16. New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate.
Takeshita A; Shinjo K; Ohnishi K; Ohno R
Jpn J Cancer Res; 1995 Jun; 86(6):607-15. PubMed ID: 7622426
[TBL] [Abstract][Full Text] [Related]
17. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52.
Kobayashi Y; Yamashiro T; Nagatake H; Yamamoto T; Watanabe N; Tanaka H; Shigenobu K; Tsuruo T
Biochem Pharmacol; 1994 Oct; 48(8):1641-6. PubMed ID: 7980629
[TBL] [Abstract][Full Text] [Related]
19. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
